Virtual Meetings 2021

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia

For more information, please contact us at or (800) 233-6153.


Amir Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Rebecca L Olin, MD, MSCE
Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Keith W Pratz, MD
Director of Leukemia Program
Hospital of the University of Pennsylvania
Associate Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Andrew H Wei, MBBS, PhD
Professor, Department of Haematology
Alfred Hospital
Monash University
Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia

Additional faculty to be announced.

Neil Love, MD
Research To Practice


Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for acute myeloid leukemia. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Optimal Management of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Not Eligible for Intensive Therapy

    MODULE 2: Current Management Approaches for Patients with AML and a FLT3 and/or IDH Mutation

    MODULE 3: Novel Induction and Maintenance Strategies for Younger Patients with AML; Promising Agents and Strategies Under Investigation

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia.

Learning Objectives

  • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
  • Appreciate the FDA approval of venetoclax in combination with azacitidine or decitabine or lowdose cytarabine for patients with newly diagnosed AML unfit for intensive therapy, and identify individuals appropriate for treatment with his novel agent.
  • Develop an understanding of the mechanisms of action of, published data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or 2 mutation and incorporate these agents into current management algorithms.
  • Reflect on available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Review Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and consider how this novel strategy can be applied in current clinical management.
  • Recall promising agents and investigational strategies under evaluation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Servier Pharmaceuticals LLC.